Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), a foreign government–owned hospital and research institution based in Rotterdam, Netherlands, operates as a federal grant recipient and subcontractor to U.S. universities and research centers, with no prime federal contracts. Erasmus MC receives project grants from the National Institutes of Health to conduct biomedical research and serves as a subcontractor on NIH-funded grants awarded to U.S. prime recipients, performing clinical studies, laboratory analysis, and disease-modeling work at its facilities in the Netherlands.

Erasmus MC's federal footprint is dominated by grant work, not contracts. As a prime recipient, Erasmus MC holds three NIH Project Grants: a $511,551 National Cancer Institute award (CFDA 93.393, Cancer Cause and Prevention Research) spanning through June 2031 for molecular detection and risk stratification of monoclonal B-cell lymphocytosis via immunoglobulin sequencing and proteomic profiling; a National Institute of Allergy and Infectious Diseases award (August 2023 through July 2028) for research into highly pathogenic avian influenza virus emergence mechanisms; and a National Cancer Institute award (September 2022 through November 2024, now completed) investigating PROTAC-mediated antigen degradation as a strategy to enhance cytotoxic T-cell responses against cancer. As a prime contractor, Erasmus MC holds two small purchase orders: a $23,815 National Institute of Mental Health professional services award (completed July 2023) and a $62,069 National Institute on Aging award (completed July 2024) for DNA extraction and genotyping services in group B streptococcal research. Combined potential value across all prime and sub awards totals $136 thousand in contracts plus $20.1 million in grant obligations.

Erasmus MC's customer concentration sits with NIH institutes. The top five NIH funding components—the National Cancer Institute (11 awards), the National Institute of Allergy and Infectious Diseases (10 awards), the National Institute of Mental Health (9 awards, $24 thousand combined potential), the National Heart Lung and Blood Institute (8 awards), and the National Institute on Aging (6 awards, $66 thousand combined potential)—account for 75% of all awards by count. The two rankings track closely across these NIH institutes; the National Institute on Aging anchors the largest dollar exposure despite lower award count, reflecting larger grant mechanisms relative to contract awards.

Activity has grown in recent years from 7 awards in 2022 to 18 in 2024, with a slight pullback to 8 awards in 2025 and 5 to date in 2026. Only one award reaches ultimate completion inside the next twenty-four months, reducing immediate recompete pressure.

Erasmus MC operates predominantly as a subcontractor (83% of 59 recent awards) and sits as a subgrantee on research teams led by U.S. universities. Named prime grantees include Columbia University (multiple grants in virology, cancer modeling, and psychiatric research), Icahn School of Medicine at Mount Sinai (influenza research, psychiatric outcomes in pregnancy), the University of Washington (cardiovascular and aging phenotype gene discovery), the University of California–Davis (comparative effectiveness breast cancer screening), Stanford University (cardiac imaging and risk stratification for non-compaction cardiomyopathy), the University of California–San Francisco (cancer screening and prevention modeling), Northwestern University (dementia risk prediction), and the Rehabilitation Institute of Chicago (balance trainer device development). Erasmus MC also subcontracts under federal service contracts, with SCI-reported activity showing 2.0 FTEs in FY2022 and 4.1 FTEs in FY2025 across two named subcontractor records, though the specific prime contractors for those service-contract roles are not detailed in the source.

Erasmus MC's research capabilities center on virology and infectious disease epidemiology (avian influenza emergence, SARS-CoV-2 fusion inhibition, T-cell epitope discovery), oncology immunotherapy and cancer risk modeling (PROTAC-mediated immune enhancement, molecular detection of lymphocytic malignancy precursors, cancer screening algorithm development), psychiatric and reproductive health research (maternal mental illness and infant development, postpartum psychosis biomarkers, schizophrenia circuit dysfunction), and health services research using Dutch population cohorts (the Rotterdam Study and Erasmus Family cohorts, which provide long-term follow-up data on 14,926 individuals across cardiometabolic, cognitive, and musculoskeletal outcomes). Work is performed at Erasmus MC facilities in Rotterdam, with performance spanning clinical recruiting, laboratory analysis, biobanking, neuroimaging, statistical modeling, and data harmonization across multi-site U.S.–Netherlands research consortia.